Trinity Biotech plc (ADR)  

(Public, NASDAQ:TRIB)   Watch this stock  
Find more results for TRIB
+0.09 (0.81%)
After Hours: 11.25 +0.05 (0.45%)
May 5, 4:00PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.80 - 11.25
52 week 9.20 - 19.03
Open 11.08
Vol / Avg. 69,866.00/76,214.00
Mkt cap 270.79M
P/E 14.62
Div/yield 0.22/1.96
EPS 0.77
Shares 95.84M
Beta 0.88
Inst. own 20%
Jul 26, 2016
Q2 2016 Trinity Biotech PLC Earnings Release (Estimated) Add to calendar
Apr 19, 2016
Q1 2016 Trinity Biotech PLC Earnings Call - Webcast
Apr 19, 2016
Q1 2016 Trinity Biotech PLC Earnings Release
Mar 14, 2016
Trinity Biotech PLC at ROTH Conference
Mar 3, 2016
Q4 2015 Trinity Biotech PLC Earnings Call
Mar 3, 2016
Q4 2015 Trinity Biotech PLC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 11.34% 21.75%
Operating margin 12.56% 13.42%
EBITD margin - 19.04%
Return on average assets 3.15% 7.19%
Return on average equity 5.34% 10.61%
Employees 568 -
CDP Score - -


IDA Business Park
BRAY, 18
+353-1-2769800 (Phone)
+353-1-2769888 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Trinity Biotech also is a provider of raw materials to the life sciences and research industries globally. Trinity Biotech markets its portfolio of almost 850 products to customers in approximately 100 countries around the world. The primary market for Trinity Biotech's diagnostic products is the Americas (which consists principally of North America and South America). Its products are classified as point-of-care, emergency medicine, clinical laboratory and blood bank screening. The Company markets products under Uni-Gold, Recombigen, Meritas, Captia, MicroTrak, Bartels, MarDx, MarBlot, Premier, Ultra2, ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ.

Officers and directors

Ronan O'Caoimh Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Kevin Tansley Chief Financial Officer, Secretary
Age: 42
Bio & Compensation  - Reuters
Rory Nealon Chief Operating Officer, Executive Director
Age: 45
Bio & Compensation  - Reuters
Eric Brouwer Ph.D. Chief Scientific Officer, and Vice President Cardiac
Bio & Compensation  - Reuters
James Walsh Ph.D. Executive Director
Age: 53
Bio & Compensation  - Reuters
Clinton H. Severson Non-Executive Director
Age: 67
Bio & Compensation  - Reuters
Denis R. Burger Ph.D. Senior Non-Executive Independent Director
Age: 70
Bio & Compensation  - Reuters
Peter Coyne Non-Executive Independent Director
Age: 53
Bio & Compensation  - Reuters
James D. Merselis Non-Executive Independent Director
Bio & Compensation  - Reuters